Which flu vaccine packs a bigger punch for people with HIV?
NCT ID NCT07644546
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will compare two enhanced flu vaccines—one with an adjuvant (MF59) and one with a higher dose—in 350 adults living with HIV. The goal is to see which vaccine triggers a stronger immune response. Participants will receive one shot and have their antibody levels checked after 28 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MF59-adjuvanted influenza vaccine and high-dose influenza vaccine
What this could lead to
If this trial succeeds, it could show which flu vaccine works best for people with HIV, leading to better protection during flu season.
What could go wrong
This trial hasn't started yet and is relatively small (350 people). Results may not apply to all people with HIV, and the vaccines may not prevent infection entirely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••